BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17187316)

  • 1. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
    Billich A
    IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
    Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
    Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
    Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
    Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
    Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
    PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
    Burakoff R; Barish CF; Riff D; Pruitt R; Chey WY; Farraye FA; Shafran I; Katz S; Krone CL; Vander Vliet M; Stevens C; Sherman ML; Jacobson E; Bleday R
    Inflamm Bowel Dis; 2006 Jul; 12(7):558-65. PubMed ID: 16804392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
    Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
    Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
    Wada Y; Lu R; Zhou D; Chu J; Przewloka T; Zhang S; Li L; Wu Y; Qin J; Balasubramanyam V; Barsoum J; Ono M
    Blood; 2007 Feb; 109(3):1156-64. PubMed ID: 17053051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
    Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
    Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
    Keino H; Watanabe T; Sato Y; Niikura M; Wada Y; Okada AA
    Arthritis Res Ther; 2008; 10(5):R122. PubMed ID: 18847496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
    Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
    PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
    Baranov MV; Bianchi F; van den Bogaart G
    Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases.
    Borchardt JK
    Drug News Perspect; 2004 Nov; 17(9):607-14. PubMed ID: 15645018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
    Ding C; Xu J; Li J
    Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effect of the low molecular weight inhibitor of the NF-kappaB signaling pathway on experimental autoimmune uveoretinitis].
    Keino H
    Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):944-54. PubMed ID: 21141074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
    Hayakawa N; Noguchi M; Takeshita S; Eviryanti A; Seki Y; Nishio H; Yokoyama R; Noguchi M; Shuto M; Shima Y; Kuribayashi K; Kageyama S; Eda H; Suzuki M; Hatta T; Iemura S; Natsume T; Tanabe I; Nakagawa R; Shiozaki M; Sakurai K; Shoji M; Andou A; Yamamoto T
    Bioorg Med Chem; 2014 Jun; 22(11):3021-9. PubMed ID: 24767819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis.
    Akiyama S; Yamada A; Micic D; Sakuraba A
    J Am Acad Dermatol; 2021 Mar; 84(3):676-690. PubMed ID: 32791083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
    Macaluso FS; Orlando A; Cottone M
    Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
    Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
    World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.